Last Posted: Dec 21, 2020
- Germline TP53 Testing in Breast Cancers: Why, When and How?
Evans D Gareth et al. Cancers 2020 Dec 12(12)
- Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations.
Suehara Yoshiyuki et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Jun
- Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
Cheng Lijun et al. BMC medical genomics 2019 Jan 12(Suppl 1) 23
- Management of Individuals at Increased Hereditary Risk
- A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial.
Lui Gabrielle et al. Journal of clinical pharmacology 2018 May
- Pediatric oncologist willingness to offer germline TP53 testing in osteosarcoma.
Shaul Eliana et al. Cancer 2018 Jan
- The role of pharmacogenetics in the treatment of osteosarcoma.
Vos Hanneke I et al. Drug discovery today 2016 Nov 21(11) 1775-1786
- Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort
Mai Phuong L et al. JAMA oncology 2017 Aug
- Pharmacogenetics in cancer therapy - 8 years of experience at the Institute for Oncology and Radiology of Serbia.
Cavic Milena et al. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 21(5) 1287-1295
- Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg Roman et al. Oncotarget 2017 Apr
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.